by Cal Strode | Jan 20, 2025
2025 marks the third time I’ve covered the Alliance for Regenerative Medicine (ARM) State of the Industry Briefing for Signals. In 2024’s installation, I noted the strong emphasis on the cell and gene therapy (CGT) industry’s acceleration, driven by scientific...
by Tyler Wenzel | Jan 16, 2025
Regenerative medicine, the biomedical field that includes the development of cell and gene therapies, is arguably the most exciting research discipline. I often reflect on how lucky I am to have found myself in this area of science. I am always excited to learn and...
by Peace Chukwu | Jan 10, 2025
A challenge in stem cell research and clinical application is the imbalance between demand and the limited availability of these stem cells. This shortage complicates the development of effective therapies and restricts treatment options for patients. Because stem...
by Stacey Johnson | Jan 2, 2025
Happy New Year! With so much information available online, thank you for choosing to read the content on Signals. Whether you are a subscriber and a loyal reader, or you follow a particular blogger or category, your readership is appreciated! As of this writing, here...
by Lyla El-Fayomi | Dec 26, 2024
Pick of the Month Another HIV-1 remission, but with a twist: The Geneva Patient I previously wrote about Mr. Paul Edmonds, who was the fifth person in history to be cured of both HIV-1 and leukemia since the first such case in 2009. This was achieved through a...
by Sara M. Nolte | Dec 19, 2024
I’m excited to be sharing some new Canadian cancer immunotherapy developments! We’ve already seen some great stuff with CAR T cells and checkpoint inhibitors. But the strength of these therapies is also their downfall: their targets make them highly specific and...
by Laya Kiani | Dec 12, 2024
The convergence of tissue engineering, regenerative medicine (TERM) and artificial intelligence (AI) has ushered in a transformative era for the biomedical field. By leveraging machine learning (ML) and deep learning (DL), researchers can enhance cell culture...
by Anis Fahandej-Sadi | Dec 5, 2024
If you’re reading this, you’re probably aware of the massive strides the cell and gene therapy (CGT) industry has made in the last few years. Between 2017 and 2022, six CGT products were approved by the U.S. Food and Drug Administration, but we saw eight approvals in...
by Stacey Johnson | Nov 29, 2024
Are you familiar with the Gartner Hype Cycle? It’s a way of separating reality from hype when it comes to emerging technologies – like cell and gene therapies (CGTs). The hype cycle employs a graph to present the maturity of new technologies as they pass through five...
by Lyla El-Fayomi | Nov 19, 2024
Millions of placentas are discarded annually around the world. Given the regenerative medical potential demonstrated by placenta-derived tissue over the years, this is quite an unfortunate statistic. First used in 1910, placenta-derived tissue was abandoned in the...
Comments